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Abstract: 
 
As part of an ongoing investigation of filamentous fungi for anticancer leads, an active culture 
was identified from the Mycosynthetix library (MSX 70741, of the order Hypocreales, 
Ascomycota). The fungal extract exhibited cytotoxic activity against the H460 (human nonsmall 
cell lung carcinoma) cell line, and bioactivity‐directed fractionation yielded peptaibols 1–12 and 
harzianums A (13) and B (14). Structure elucidation of 1–12 was facilitated by high‐resolution 
MS/MS using higher‐energy collisional dissociation and by high field NMR (950 MHz). The 
absolute configuration was determined by Marfey's analysis of the individual amino acids; the 
time required for such analysis was decreased via the development of a 10‐min ultra performance 
liquid chromatography method. The isolated peptaibols (1–12), along with three other peptaibols 
isolated and elucidated from a different fungus (MSX 57715) of the same order (15–17), were 
examined for activity in a suite of biological assays, including those for cytotoxic, antibacterial, 
and anthelmintic activities.  
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Article: 
 
Introduction 
 
By most measures of scientific progress, peptaibols have been investigated rather extensively. 
An entire book [1] and an issue of a two separate journals [2, 3] have been devoted to the 
subject, and various aspects have been reviewed extensively, especially when dealing with a 
common source (Trichoderma sp.) [4] or the most well‐studied class of peptaibols (the 
alamethicins) [5]. However, in the course of a collaborative project to identify anticancer leads 
from diverse natural product sources [6, 7], extracts of filamentous fungi from the 
Mycosynthetix library, representing over 55 000 accessions, have not yielded peptaibols to date. 
In fact, most of the compounds discovered in this program, which is driven by bioactivity‐
directed fractionation guided by a suite of cytotoxicity and mechanism of action‐based assays, 
have been of a molecular weight (MW) well under 1000 amu [8-11]. Hence, uncovering a series 
of both new and known compounds of significantly greater MW was of interest, both from the 
standpoint of evaluating their biological activity in assays that pertain to anticancer activity and 
from examining their chemical diversity relative to the library of fungal isolates. 
 
 
Figure 1. Structure of alamethicin F50 (8) and sequences of the other isolated peptaibols. 
 
In the course of this research, state‐of‐the‐art technologies were applied to the structure 
elucidation processes, thereby developing tools that could be applied to research on peptaibols or 
related compounds. For example, determining the sequence of residues was facilitated via the 
use of ultra performance liquid chromatography (UPLC) coupled to high‐resolution MS/MS 
using higher‐energy collisional dissociation (HCD) on a Thermo LTQ Orbitrap XL (Thermo 
Fisher Scientific, Waltman, MA, USA). This was complemented by the resolution enhancements 
observed when analyzing the TOCSY and NOESY spectra on a 950‐MHz NMR spectrometer. 
Moreover, the time required to determine the absolute configuration of the residues with the use 
of Marfey's analysis was decreased by the development of a 10‐min UPLC procedure, compared 
with 30‐ to 40‐min run times for similar analyses of peptaibols by HPLC [12, 13]. In short, the 
bioactivity‐directed fractionation study of fungus MSX 70741 resulted in the isolation and 
characterization of a series of peptaibols (1–12; compounds 1–7 and 12 being new) and two 
known trichothecene analogues [harzianum A (13) and harzianum B (14)]. The isolated 
peptaibols (1–12), along with three other known peptaibols (15–17) isolated from a different 
fungus of the same order (MSX 57715), were examined for cytotoxicity, antibacterial and 
anthelmintic activities, and activity in a mitochondrial transmembrane potential assay. 
Figure 1 illustrates the structures/sequences for the isolated peptaibols (1–12 and 15–17). 
 
Materials and Methods 
 
General Experimental Procedures 
 
NMR experiments were conducted in CD3OH with presaturation of the OH peak at δH 4.9 ppm. 
NMR instrumentation was a Bruker Ultrashield Plus with Avance III console, Topspin software 
version 2.1, and a QNP style Cryoprobe (operating at 950.30 MHz for 1H; Bruker BioSpin Corp., 
Billerica, MA, USA). For comparison of these NMR data with that of a 500‐MHz spectrometer, 
a JEOL ECA‐500 (JEOL Ltd., Tokyo, Japan) was utilized. HRESI‐MS was performed on a 
Thermo LTQ Orbitrap XL system equipped with HCD cell. UPLC was carried out on a Waters 
Acquity system with data collected and analyzed using Empower software (build 2154; Waters 
Corp., Milford, MA, USA). Preparative HPLC was performed on Varian Prostar HPLC systems 
equipped with Prostar 210 pumps and a Prostar 335 photodiode array detector, with data 
collected and analyzed using Galaxie Chromatography Workstation software (version 1.9.3.2; 
Walnut Creek, CA, USA). For preparative HPLC, a Phenomenex Synergi Max‐RP 80 (4 µm; 
250 × 21.2 mm; Phenomenex, Inc., Torrance, CA, USA) column was used at a 15 ml/min flow 
rate, whereas for UPLC, a BEH C18 (1.7 µm; 50 × 2.1 mm; Waters Corp.) column was used with 
a 0.61 ml/min flow rate (0.5 ml/min for Marfey's analysis), both monitored at 205 nm (340 nm 
for Marfey's analysis). Flash chromatography was performed on a Teledyne ISCO CombiFlash 
Rf (Teledyne‐Isco, Lincoln, NE, USA) using a 40‐g Silica Gold column and monitored by UV 
and evaporative light‐scattering detectors. Reference standards of amino acids and Marfey's 
reagent were obtained from Sigma‐Aldrich (St. Louis, MO, USA). All other reagents and 
solvents were obtained from Fisher Scientific and were used without further purification. 
 
Producing Organisms and Fermentations 
 
Mycosynthetix fungal strain MSX 70741 was isolated in April 1993 from wood collected in a 
humid mountain forest, and strain MSX 57715 was isolated in October 1991 from leaf litter from 
a predominately oak, humid forest, both by Dr Barry Katz of MYCOsearch and later acquired by 
Mycosynthetix. DNA analyses were performed by MIDI Labs, Inc. (Newark, DE), and the D2 
variable region of the large subunit (LSU) rRNA was sequenced and compared with their 
database; in both cases, the closest match could only determine that these fungi were of the order 
Hypocreales, Ascomycota; these data were deposited in Genbank (accession nos. JN377382 and 
JN377381, respectively). The cultures were stored on malt extract slants and were transferred 
periodically. Fresh cultures were grown on a similar slant, and a piece was transferred to a 
medium containing 2% soy peptone, 2% dextrose, and 1% yeast extract (YESD media). 
Following incubation (7 days) at 22 °C with agitation, the cultures were used to inoculate 50 ml 
of a rice medium, prepared using rice to which was added a vitamin solution and twice the 
volume of rice with H2O, in a 250‐ml Erlenmeyer flask. This was incubated at 22 °C until the 
cultures showed good growth (approximately 14 days) to generate the screening cultures. The 
scale‐up cultures, used for isolation of the peptaibols, were grown in a 2.8‐l Fernbach flask 
containing 150‐g rice and 300‐ml H2O and were inoculated using a seed culture grown in YESD 
medium. These were incubated at 22 °C for 14 days. 
 
Extraction and Isolation 
 
To the large scale solid fermentation of MSX 70741 was added 500 ml of 1 : 1 MeOH/CHCl3. 
The mixture was shaken for 16 h then filtered, and the solvent was evaporated. The material 
(2.07 g) was then dissolved in 1 : 1 CHCl3/MeOH and adsorbed onto Celite 545 (Sigma‐Aldrich) 
and fractionated by flash silica gel chromatography. The solvent conditions were 100% hexane 
to 100% CHCl3 over 10 column volumes (CV), then 100% CHCl3 for 7 CV, followed by 
increasing amounts of MeOH in CHCl3 from 0 to 10% over 20 CV, 10 to 20% over 5 CV, 20 to 
100% over 2 CV, and 100% MeOH for the remaining 8 CV, all at 40 ml/min. The peptaibol‐
enriched material (100% MeOH; 600 mg) was purified via six separate injections on preparative 
HPLC using a gradient that initiated with 40 : 60 CH3CN/H2O and increased linearly to 100 : 0 
CH3CN/H2O over 30 min. 
 
UPLC‐HRMS of 1–12 and 15–17 
 
High‐resolution UPLC‐MS was carried out on a Waters Acquity UPLC system coupled to 
Thermo LTQ Orbitrap XL. Sample injections of 3 µl of 0.5 mg/ml were separated via UPLC at 
0.61 ml/min; an in‐line column flow tee was used to divert the mobile phase 1 : 1 between the 
electrospray source and waste. UPLC conditions were 20% CH3CN in 0.1% aqueous formic acid 
for 0.5 min., then 20–100% CH3CN from 0.5 to 3.0 min. Peptaibols have a labile bond between 
the central Aib and Pro residues that is cleaved under conventional ESI conditions [14]. As a 
result, two fragments (referred to as in‐source fragments henceforth) are commonly observed at 
higher abundance than that of the monoisotopic parent ion. Mass spectra were collected in 
positive mode ESI with the following source parameters: capillary temperature, 275 °C; sheath 
gas, 15; auxiliary gas, 5; sweep gas, 2; source voltage, 4.50 kV; capillary voltage, 46 V; and tube 
lens, 115 V. The MS/MS fragmentation was performed using an instrument method composed of 
four scan events. During scan event 1, a full‐scan mass spectrum of mass range 75–2000 amu 
was collected; scan event 2 was used to conduct HCD fragmentation of the low MW fragment 
(in‐source) at an optimized collision energy of 22 (Table 1); scan event 3 was used to perform 
HCD fragmentation of the high MW fragment (in‐source) at a collision energy of 15; and scan 
event 4 was for HCD fragmentation of the high MW fragment (in‐source) at a collision energy of 
35. 
 
Collision energies selected in this study were optimized using the LTQ Tune software's 
automatic tuning feature (Thermo Fisher Scientific). To do so, a pure solution of a selected 
peptaibol was infused directly under UPLC flow conditions. In‐source fragments were then 
subjected to a range of collision energies [10–35 normalized collision energy (NCE); NCE is a 
resonance excitation process used for inducing fragmentation while compensating for mass 
dependence]. Fragmentation energies used in this study were selected to generate a broad MW 
range of fragments of the highest signal possible. MSn of the large (in‐source) fragment was 
collected at two different fragmentation energies (15 and 35 NCE) during two different scan 
events because we were not able to produce all of the observed fragments at a single NCE value. 
 
Table 1. High‐resolution mass data for compounds 1–12 
Compound [M + H]+ Theoretical [M + H]+ Mass error (ppm) Formula Low MW fragment High MW fragment 
1 1949.1166 1949.1219 −2.7 C91H149N23O24 774.4487 1175.6748 
2 1979.1276 1979.1324 −2.4 C92H151N23O25 774.4483 1205.6868 
3 1993.1443 1993.1480 −1.9 C93H153N23O25 788.4641 1205.6873 
4 1949.1136 1949.1219 −4.2 C91H149N23O24 774.4479 1175.6745 
5 1979.1300 1979.1324 −1.2 C92H151N23O25 774.4482 1205.6870 
6 1949.1145 1949.1218 −3.8 C91H149N23O24 774.4482 1175.6758 
7 1120.7307 1120.7340 −3.0 C55H97N11O13 512.3060/609.4315/920.5790* 
8 1963.1321 1963.1375 −2.8 C92H151N23O24 774.4478 1189.6898 
9 1977.1481 1977.1532 −2.6 C93H153N23O24 788.4638 1189.6911 
10 1977.1468 1977.1532 −3.2 C93H153N23O24 774.4478 1203.7051 
11 1978.1309 1978.1371 −3.2 C93H152N22O25 775.4318 1203.7056 
12 1992.1476 1992.1528 −2.6 C94H154N22O25 789.4475 1203.7075 
* Three major in‐source fragments were present with compound 7. 
 
Marfey's Analysis of 1–12 
 
Our method was based on Kjer et al. [15] with the following modifications. Approximately 
0.2 mg of each amino acid standard was weighed into separate glass 2‐ml reaction vials. To each 
standard was added 50 µl of H2O, 20 µl of 1 m NaHCO3, and 100 µl 1% Marfey's reagent in 
acetone. The reaction mixtures were agitated at 40 °C for 1 h. The reactions were halted by the 
addition of 10 µl of 2N HCl. The product of the reactions was dried under a stream of air and 
dissolved in ~1.7 ml of MeOH. Each derivatized standard was injected individually (0.7 µl) onto 
the UPLC. Also, aliquots of all of the derivatized standards were combined to give a mixed 
standard, which was injected just prior to the digested and derivatized peptaibols (see succeeding 
discussion). UPLC conditions were 10–70% MeOH in H2O over 10 min on the aforementioned 
BEH column and eluent monitored at 340 nm. 
 
To generate the digested and derivatized peptaibols, approximately 0.2–0.3 mg of compounds 1–
12 were weighed separately into 2‐ml reaction vials, to which was added 0.5 ml of 6N HCl. The 
compounds were hydrolyzed at 110 °C for 24 h, at which time they were evaporated under a 
stream of air. To each hydrolysis product was then added 25 µl H2O, 10 µl 1 m NaHCO3, and 
50 µl of 1% Marfey's reagent in acetone. The reaction mixtures were agitated at 40 °C for 1 h. 
The reactions were halted by the addition of 5 µl of 2N HCl. The mixtures were dried under a 
stream of air and brought up in ~200 µl of MeOH and injected onto the UPLC with the use of the 
same conditions as for the standards. 
 
Cytotoxicity Assays 
 
The cytotoxicity measurements against the MCF‐7 [16] human breast carcinoma (Barbara A. 
Karmanos Cancer Center), NCI‐H460 [17] human large cell lung carcinoma (HTB‐177, 
American Type Culture Collection (ATCC)), and SF‐268 [18] human astrocytoma (NCI 
Developmental Therapeutics Program) cell lines were performed as described 
previously [19, 20]. Moreover, a second cytotoxicity assay was performed on only the isolated 
compounds using the MDA‐MB‐435 [21] human melanoma (HTB‐129, ATCC) cell line as 
described previously [8] and with the following modifications. After treating the MDA‐MB‐435 
cells with test substances and 96 h incubation at 37 °C, the cells were evaluated for viability with 
a commercial absorbance assay (CellTiter 96 AQueous One Solution Cell Proliferation Assay, 
Promega Corp, Madison, WI, USA). The compounds were also tested in the IMR90 fibroblast 
cell line (ATCC CCL‐186) [22], a normal diploid cell line that proliferates in culture for 
approximately 58 generations prior to senescence. Positive control data for all cell lines are 
provided in the legend of Table 2. 
 
Table 2. Biological activities of peptaibols 1–12 and 15–17 
Compound Cytotoxicity IC50 values (in μm)a MICb (µg/ml) IC50c (µg/ml) 
MCF‐7 H460 SF268 IMR90 MDA‐MB‐435 Staphylococcus aureus MRSA Haemonchus contortus 
Atroviridin D (1) >10 >10 >10 >10 NTd NT NT NT 
Atroviridin E (2) 3.3 3.0 6.8 7.7 NT NT NT NT 
Atroviridin F (3) 3.8 3.2 5.3 >10 NT NT NT NT 
Atroviridin G (4) 2.7 1.3 1.9 5.9 NT NT NT NT 
Atroviridin H (5) 1.8 2.5 4.4 6.1 NT NT NT NT 
Atroviridin I (6) 2.1 2.3 5.1 9.8 NT 44 44 NT 
Trichobrachin D‐I (7) 3.4 4.1 7.0 >10 7.3 113 113 NT 
Alamethicin F50 (8) 2.2 3.4 2.3 4.8 8.9 35 140 0.2 
Atroviridin B (9) 1.3 2.5 1.9 3.6 4.2 6 13 0.4 
Polysporin B (10) 1.3 2.0 1.5 2.9 3.2 102 102 NT 
Alamethicin II (11) 1.1 1.6 1.7 4.0 6.2 12 23 NT 
Atroviridin J (12) 1.0 1.0 2.6 5.2 NT 9 18 NT 
Trichokonin VI (15) 2.3 2.7 2.0 4.5 3.8 21 43 NT 
Trichokonin VII (16) 1.3 2.2 1.5 5.1 3.0 8 17 >8.3 
Longibranchin BIII (17) 0.8 0.8 1.4 4.6 NT 4 8 3.0 
Camptothecine 0.05 0.008 0.03 0.18 NT NT NT NT 
Vinblastinee NT NT NT NT f NT NT NT 
Vancomycine NT NT NT NT NT 1.5 0.8 NT 
Ivermectine NT NT NT NT NT NT NT 0.006 
a IC50 values were determined as the concentration required to reduce cellular proliferation 
by 50% relative to untreated controls following 72 h of continuous exposure (96 h for MDA‐
MB‐435). 
b Minimal inhibitory concentration is the lowest concentration of compound completely 
inhibiting growth as expressed in µg/ml [19]. 
c IC50 values were determined as the concentration required to inhibit larval motility by 50% 
relative to untreated controls following 72 h of continuous exposure as expressed in µg/ml. 
d Indicates ‘not tested’. 
e Positive controls. 
f The positive control for MDA‐MB‐435 was vinblastine tested at 2.0 and 1.0 nm, which 
resulted in 41 and 68% viable cells after treatment, respectively. 
 
 
 
Antimicrobial Assay 
 
The compounds were screened initially for antimicrobial activity with the use of an agar plate 
diffusion assay. Overnight cultures of Escherichia coli, Pseudomonas 
aeruginosa, Staphylococcus aureus, Mycobacterium smegmatis, Candida albicans, and Bacillus 
subtilis were used to inoculate molten LB media or Middlebrook 7H9 media (Difco Inc., Becton, 
Dickinson & Company, Sparks, MD, USA) with 1% glycerol, containing 1.5% agar and kept at 
50 °C; these were then used to prepare assay plates. Samples (dissolved in 10 µl MeOH) were 
applied to the surface of the assay dish, and positive controls were treated in a similar manner 
(penicillin G, gentamicin, novobiocin, and streptomycin; all from Sigma). The bioassay plates 
were incubated overnight at 37 °C. Biological activity of the standards could be detected to 
1 µg/ml (except that penicillin G was active against E. coli at 100 µg/ml only). 
 
Measurement of Antibiotic Activity against Methicillin‐resistant Staphylococcus aureus 
 
The samples were tested against a suite of methicillin‐resistant S. aureus (MRSA) isolates (data 
not shown); only representative data are shown in Table 2 against S. aureus (ATCC 6538) and an 
unrelated MRSA strain (ATCC 43300), which were both acquired from Danville Community 
Hospital (Danville, VA, USA). Minimal inhibitory concentration (MIC) measurements were 
performed as described previously [23, 24]. All measurements were made in duplicate, and 
susceptibilities of the strains to vancomycin as a positive control were measured in parallel. 
 
Anthelmintic Assay 
 
The compounds were screened against Haemonchus contortus infective larvae (HcL3) in an L3 
motility assay; this assay evaluates the effect of the compounds on the body wall musculature 
because this is not a feeding stage. Third stage larvae of an isolate of H. contortus maintained in 
goats were obtained from the laboratory of Dr Raymond Kaplan (University of Georgia, Athens, 
GA). The nematode L3 bioassay was as described [25] with slight modifications. Briefly, in a 
15‐ml centrifugation tube, HcL3s were incubated at room temperature in a 0.15% sodium 
hypochlorite solution for 25 min, centrifuged at 100 rcf for 5 min, and then the supernatant was 
removed and rinsed with distilled H2O. HcL3s were concentrated in phosphate buffered saline to 
contain approximately 800 HcL3s/ml. The L3 motility assay was conducted in triplicate in 96‐
well plates; each well had a total volume of 75 µl and contained roughly 50 exsheathed HcL3s. 
Plates were incubated in a humidified chamber at 25–30 °C for 72 h, and percent immobility was 
calculated. Ivermectin (positive control) and DMSO only (negative control) wells were included 
on every plate, and percent immobility was calculated using the mean counts from three 
replicates. The peptaibols were dissolved in DMSO and evaluated at 20 µg/ml in triplicate; 
compounds were considered active if they had any immobilizing effects on HcL3s. Active 
compounds were evaluated further in dose response, and IC50 values were calculated using a log 
probit regression analysis. 
 
Mitochondria Transmembrane Potential Assay 
 
The mitochondrial transmembrane potential assay was performed as described previously [8]. 
 
Results 
 
The crude 1 : 1 CHCl3/MeOH extract of fungus MSX 70741 was partitioned with 4 : 1 : 5 
CHCl3/MeOH/H2O. The organic soluble material was active (>95% growth inhibition of H460 
cells at 20 µg/ml) and was fractionated initially by flash silica gel chromatography. Harzianum A 
(13, 6.8 mg) [26] and harzianum B (14, 0.9 mg) [27] were eluted in the 4–5% MeOH in 
CHCl3 fraction (>96% growth inhibition of H460 at 2 µg/ml); these were purified by HPLC, and 
their NMR data were in excellent agreement with the literature [Figure S1 for structures 
of 13 and 14 (Supporting Information)] [27]. The peptaibols were eluted in the flash 
chromatography system in the 100% MeOH fraction (>98% growth inhibition of H460 at 
20 µg/ml). Final purification of the peptaibols was accomplished by preparative scale RP‐HPLC 
(Figure S2). Compound 1 was eluted at 12.0 min (1.1 mg), 2 at 13.1 min (3.3 mg), 3 at 14.0 min 
(0.7 mg), 4 at 14.3 min (2.0 mg), 5 at 15.7 min (2.6 mg), 6 at 17.7 min (6.7 mg), 7 at 18.7 min 
(12.4 mg), 8 between 19 and 21 min (242.5 mg), 9 between 21.3 and 22.3 min 
(77.6 mg), 10between 22.3 and 23.5 min (52.6 mg), 11 between 23.5 and 24.5 min (28.8 mg), 
and 12 at 25.3 min (4.1 mg). With the use of the same conditions as mentioned previously, 
fungus MSX 57715 was extracted and fractionated to isolate 
peptaibols 15 (205.6 mg), 16 (93.6 mg), and 17 (7.5 mg) with HPLC elution times of 17–19, 19–
20.5, and 21.1 min, respectively. Compounds 8–11 were the major isolates and were known 
peptaibols, whereas 1–7 and 12were new. The numbering of these compounds corresponds to 
their elution order on RP‐HPLC: 1 eluted earliest and 12 eluted latest. 
 
The high‐resolution protonated monoisotopic precursor ion data, [M + H]+, and the resultant 
molecular formulae for compounds 1–12 are listed in Table 1; the structure for 8 and the 
sequence for the other peptaibols are displayed in Figure 1. An important characteristic of the 
MS spectra for typical 20‐residue peptaibols was in‐source fragmentation between the Aib13 and 
Pro14 residues, leaving two major fragments (Figure 2) [14]. Other diagnostic peaks were the 
doubly and triply charged species, as well as the triply charged dimer (Figure 2). The MS data 
for the two major fragments (termed here ‘low MW fragment’ and ‘high MW fragment’) of 1–
12 are listed in Table 1; note that 7 had three major in‐source fragments. These major fragments 
were then subjected to MS/MS to elucidate the sequence. 
 
 
Figure 2. Full‐scan HRMS (single scan) of atroviridin D (1). The two diagnostic in‐source 
fragments are apparent at 774.4487 (low MW fragment) and 1175.6748 (high MW fragment). 
The multiply charged species are apparent at 650.7113 [M + 3H]3+, 975.5646 [M + 2H]2+, and 
1300.4180 [2M + 3H]3+. 
 
The MS/MS data, in conjunction with the NMR data, were used to sequence the major 
metabolite (8), identified as the known peptaibol alamethicin F50 (or atroviridin A) [28]. The 
absolute configuration of 8 was confirmed by Marfey's analysis. As with all of the peptaibols 
isolated in this study, the individual amino acids had the l‐configuration except for Iva, which 
had d‐configuration. Compounds 9–11 were likewise found to be the known compounds 
atroviridin B (9) [29], polysporin B (10) [30], and alamethicin II (11) [31]. 
 
The sequences and structures of compounds 1–7 and 12 were elucidated in a similar fashion by 
MS/MS, NMR, and Marfey's analysis. Examples of MS/MS analysis (Figure 3), 1H NMR and 
NOESY spectra (Figures 4 and 5, respectively), and Marfey's analysis (Figure 6) are provided. 
Because of paucity of material, quality NMR data for compounds 1 and 3 could not be obtained; 
however, MS/MS and Marfey's analyses were sufficient for the complete structure elucidation 
for 1. Alternatively, structure 3 should be considered tentative because the locations of 
Val versus Iva could not be determined unequivocally, because both were present in the Marfey's 
analysis. It is highly likely that residues 9 and 15 were Val and residue 17 was Iva, because of 
similarity with known peptaibols; however, this could not be proven. 
 
 
 
Figure 3. HR‐MS/MS by HCD of atroviridin D (1): (A) HCD of 774 peaks, CE = 22; (B) HCD 
of 1175 peaks, CE = 15; (C) HCD of 1175 peaks, CE = 35. 
 
 
Figure 4. 1H NMR spectrum of atroviridin J (12) (CD3OH, 950 MHz). Spectrum was obtained 
with presaturation of the –OH peak at δH 4.9. 
 
 
Figure 5. NOESY spectrum of atroviridin J (12), highlighting the correlations proving the 
position of the Iva (J) residue (CD3OH, 950 MHz). 
 
In work of a similar vein from another fungus from the Mycosynthetix library (specifically, 
MSX 57715), other known peptaibols were isolated and elucidated, along with trichodermin, 
which is a simple trichothecene. These peptaibols were identified as trichokonin VI (15) [32], 
trichokonin VII (16) [32], and longibranchin BIII (17) [33, 34]. These peptaibols were evaluated 
in the same bioassays as 1–12 to determine the significance of Pro2 versus Ala2. 
The isolated peptaibols were evaluated in a series of biological assays. With respect to anticancer 
activity, they were tested for cytotoxicity against a panel of human tumor cell lines and a human 
fibroblast cell line (Table 2). They were also examined for activity in a mitochondria 
transmembrane potential assay but found inactive (data not shown). With literature precedent for 
antimicrobial activity for some peptaibols [35], they were tested against a battery of assays, 
including those for Gram‐positive and Gram‐negative bacteria and C. albicans. The most 
promising antimicrobial activity was with respect to S. aureus, which spawned further 
examination against MRSA (Table 2). Finally, a few peptaibols have been reported to have 
anthelmintic activity [36, 37], and thus the compounds were examined in an assay for larval 
motility against H. contortus infective stages. Larval motility was inhibited completely by four 
of the peptaibols (8, 9, 16, and 17) when tested at 20 µg/ml; these were evaluated further for dose 
response with a top concentration of 8.3 µg/ml (Table 2). In summary, the biological potential of 
these compounds were examined extensively. 
 
 
Figure 6. Marfey's analysis of atroviridin E (2). Note that the peak in the sample hydrolysate at 
3.4 min that appears to indicate the presence of d‐serine is an artifact of the derivatization 
reaction that was present in all hydrolysate chromatograms. The retention times, while close, do 
not match. For procedure and chromatographic conditions, see Section on Marfey's Analysis 
of 1–12. 
 
Discussion 
 
In this work, a single injection on UPLC‐MS/MS using HCD on a Thermo LTQ Orbitrap XL 
gave high‐resolution fragmentation and nearly complete sequence data in a 3‐min run. HCD 
fragmentation is becoming a routine tool in proteomics research, especially for quantitation 
studies that utilize various isotopic‐labeling methods and for peptide sequencing studies [38]; to 
the best of our knowledge, this technique has not been applied previously to research on 
peptaibols. The advantages of the HCD collision cell in the LTQ Orbitrap XL system include its 
ability to generate ‘rich’ fragmentation spectra that include low m/z values and Orbitrap (high‐
resolution/high mass accuracy) detection of mass fragments, allowing for molecular formula 
assignment of a given m/z value [39]. 
 
Compound 1 was identical to the major metabolite 8 except for the substitution of Ala1 for Aib1. 
To our knowledge, the only other peptaibol that has been reported to have Ala1 is trichokonin 
IIb [40], which was identical to 1 except for the replacement of Pro2 with Ala2. The result of 
substituting Aib1 with Ala1 on the cytotoxic activity was interesting, as 1 was inactive compared 
with 8 (Table 2). 
 
Compounds 2–6 were also structurally related to alamethicin F50 (8; Figure 1). 
Compounds 2and 4–6 differed from 8 by a single amino acid residue substitution. Residue 6 
appeared to be the most variable site, with substitution of Ser, Gly, or Aib for Ala. 
Compound 2 was identical to 8 except for substitution of Ser6 for Ala6. Compound 3 likely 
included Iva17 instead of Aib17 in addition to Ser6 versus Ala6, although the structure 
elucidation of 3 was incomplete because of paucity of material. Compound 5 was identical 
to 8 except for substitution of Ser4 for Ala4. Compound 6 was identical to 8 except for 
substitution of Val12 for Leu12. Compound 12 was more closely related to alamethicin II (11) 
and differed from 11only by substitution of Iva17 for Aib17. Because of their similarity to the 
known atroviridins, compounds 1–6 and 12 were ascribed the trivial names of atroviridin D 
through atroviridin J (Figure 1), respectively. 
 
Compound 7 was unique with respect to the other peptaibols isolated from MSX 70741 
(Figure 1), in that 7 contained 11 amino acid residues, whereas the others were 20‐mers. Also, 
the HRMS of 7 showed three major in‐source fragments instead of two, as with the other 
peptaibols (Figure 7). The 1H NMR also showed a methyl triplet at δH 0.85 (Figure 8), and from 
2D TOCSY and NOESY spectra, this triplet was due to Ile at residue 4. Ile was not present in 
any of the other peptaibols in this study. Compound 7 was most closely related to the 
trichobrachin [41, 42], hypomurocin [43], and trichobrevin [44, 45] subclasses of 11‐mer 
peptaibols. The effect of a shorter chain on cytotoxic activity was negligible (Table 2), although 
it seemed to diminish antibacterial activity (Table 2) and was inactive in the HcL3 motility assay 
at 20 µg/ml. The NMR data for 7 illustrated the benefit of higher field on resolution (Figure 8). 
The Ile4 methyl triplet for 7 was fully resolved at 950 MHz, whereas at 500 MHz, the triplet 
could not be identified because of overlap with the adjacent methyl doublets from the Leu8 
residue. Four methyl doublets from δH 0.90 to 0.95 were also completely resolved at 950 MHz, 
whereas at 500 MHz, there was too much overlap to distinguish the signals. The 950‐MHz NMR 
data were not only well resolved for the methyl peaks of compound 7 but it also resulted in 
greatly improved resolution of NH–NH correlations, which were essential for sequencing. 
Although it is well appreciated in the natural products community that higher field provides 
better resolution, the example of 500‐MHz versus 950‐MHz NMR spectra of 
compound 7 provides a cogent example of how this can be applied to structure elucidation of 
peptaibols. Compound 7 most closely resembled trichobrevin B‐IIb [45], having the same 
‘rough’ amino acid sequence; meaning that the Leu/Ile and Val/Iva residues were not 
unambiguously determined for trichobrevin B‐IIb. As compound 7 also closely resembled the 
trichobrachin peptaibol series, it was ascribed the trivial name trichobrachin D‐I, to differentiate 
it from the trichobrachin A series (which all have Asp2, Aib9, and Pro10), the trichobrachin B 
series (which contain Asp2, Val9, and Pro10), and the trichobrachin C series (which have Gln2, 
Aib9, and Pro10). All trichobrachins, including 7, are also characterized by Aib5 and 
Pro6 [41, 42]. 
 
 
Figure 7. Full‐scan HRMS (sum of eight mass spectra) of Trichobrachin D‐I (7). 
 
 
Figure 8. Comparison of the upfield methyl region of the 500‐MHz versus 950‐MHz 1H NMR 
data of trichobrachin D‐I (7). 
 
Compounds 2, 3, and 5 were novel in that they contain Ser at positions 4 or 6, which, to the best 
of our knowledge, has not been reported previously in 20‐mer peptaibols. Although Ser2 has 
been reported in a number of classes of 18‐mer peptaibols, such as the hypomurocin B 
series [43], the trichokindins [46], the trichorzin MA series [47], and the trichorzin PA 
series 33, 34, the presence of Ser2 is rare for 11‐mer peptaibols (as in compound 7), having only 
been reported in the trichobrevin B class [44, 45]. The presence of Ser in 2, 3, 5, and 7, 
according to the MS/MS fragmentation work, was confirmed by the TOCSY NMR spectra 
(except for 3) as well as the Marfey's analyses, which also confirmed the stereochemistry as l‐Ser 
(Figure 6). 
 
Three known peptaibols were isolated from a second Mycosynthetix fungus (MSX 57715; 
Figure 1). Trichokonin VI (15) was the major peptaibol isolate and was identical to alamethicin 
F50 (8), except for replacement of Pro2 with Ala2; compounds 8 and 15 had nearly the same 
cytotoxic activity profile (Table 2). Trichokonin VII (16) was analogous to atroviridin B (9) with 
the same substitution of Ala2 for Pro2; these two compounds were essentially equipotent in the 
cytotoxicity and antibacterial assays (Table 2). Longibranchin BIII (17) substituted Glu18 for 
Gln18 of trichokonin VII (16); the former was slightly more potent in both cytotoxicity and 
antibacterial assays (Table 2), although possibly within experimental error of the assays. 
 
A range of bioactivities were observed for the isolated peptaibols (Table 2). Several of the 
peptaibols exhibited not only cytotoxicity but also cancer cell selectivity (Table 2). Selectivity 
was assessed via the IMR90 cell lines, and they are nontransformed but proliferating cells. For 
example, the positive control camptothecin exhibited 3.6‐fold selectivity in MCF‐7 cells to 23‐
fold selectivity in H460 cells relative to IMR90 cells. Alamethicin II (11), atroviridin J (12), 
trichokonin VII (16), and longibranchin BIII (17) were most noteworthy in exhibiting 3.6‐fold, 
5.2‐fold, 3.9‐fold, and 5.8‐fold selectivity, respectively, in MCF‐7 versus IMR90 cells. These 
data were consistent with a previous report of the growth inhibitory activity of trichokonin VI 
(15) against hepatocellular carcinoma cells, in which 15 did not obviously affect normal liver 
cells at lower concentrations [48]. Three of these four compounds contained Iva17 and were the 
more hydrophobic peptaibols. A general trend of higher activity with higher hydrophobicity has 
been reported previously [42], although the effect was much less pronounced in our work. With 
respect to antibacterial activity, the compounds were essentially equipotent to both S. aureus and 
MRSA (or within experimental error), except compound 8, which was approximately four times 
more potent against S. aureus than MRSA. Compound 8 was also the most potent in the assay 
for larval motility against H. contortusinfective stages, although still two orders of magnitude 
less potent than the positive control. 
 
In summary, a series of twelve structurally related peptaibols (1–12) were isolated from MSX 
70741, including eight new peptaibols, four of which featured the incorporation of serine. These 
peptaibols were sequenced by MS/MS using HCD. The method was designed to enable full‐scan 
intact mass analysis followed by sequential fragmentation of the low and high MW fragments 
from a single UPLC injection. This streamlined approach enabled nearly complete amino acid 
sequencing capabilities of peptaibols from a small volume of sample, over a tenfold decrease in 
separation time, and accurate mass measurements to confirm amino acid identities. 
Fragmentation of peptaibols by high resolution was important because some peptaibols contain 
both Leu (and/or Ile) as well as hydroxyproline residues, an example of which is 
clonostachin [49]. Leu, Ile, and hydroxyproline fragments have the same nominal mass (113); 
however, hydroxyproline has a different formula and therefore can only be distinguished in MS 
by high‐resolution measurements. Leu and Ile have the same formula and therefore have to be 
distinguished by NMR. The NMR experiments confirmed the sequencing of the peptaibols and 
were critical for distinguishing the locations of constitutional isomers that were present in the 
same compound, such as Leu and Ile in compound 7 or Val and Iva in compound 12. The 
Marfey's analysis was also a good demonstration of the power of UPLC compared with HPLC, 
where analyses were completed in 10 min with excellent resolution of the amino acid‐Marfey 
derivative standards. Finally, from a mycological perspective, both organisms were prolific 
producers of peptaibols, generating >400 mg (MSX 70741) and >300 mg (MSX 57715) of 
peptaibols per solid phase culture in a 2.8‐l Fernbach flask, using standard techniques with no 
growth optimization studies. 
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